The Efficacy of Everolimus and Sunitinib in Patients with Sporadic or Germline Mutated Metastatic Pancreatic Neuroendocrine Tumors

被引：0
作者：
Nunez, J. E. [1 ]
Donadio, M. [2 ]
Rocha Filho, D. [3 ]
Rego, J. [4 ]
Barros, M. [2 ]
Formiga, M. N. [2 ]
Lopez, R. [5 ]
Riechelmann, R. [2 ]
机构：
[1] AC Camargo Canc Ctr, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
[2] AC Camargo Canc Ctr, Sao Paulo, Brazil
[3] Hosp Univ Walter Cantidio, Fortaleza, Ceara, Brazil
[4] Hosp Univ Onofre Lopes, Natal, RN, Brazil
[5] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
来源：
NEUROENDOCRINOLOGY | 2019年 / 108卷
关键词：
neuroendocrine; pancreatic net; metastatic net; everolimus; sunitinib; men1; multiple endocrine neoplasia type 1; vhl; von-hippel-lindau; germline mutation; sporadic;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
I11
引用
收藏
页码：176 / 176
页数：1
相关论文
共 50 条
  • [31] Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea
    Lee, Kyong Joo
    Cho, Jae Hee
    Lee, Sang Hyub
    Song, Si Young
    Lee, Kwang Hyuk
    Jeong, Seok
    Ryu, Ji Kon
    Woo, Sang Myung
    Bang, Seungmin
    Lee, Jong Kyun
    Lee, Tae Hoon
    Paik, Woo Hyun
    Kim, Yong Tae
    Lee, Woo Jin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (04) : 799 - 805
  • [32] Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors
    Pavel, Marianne E.
    Chen, David
    He, Wei
    Cushman, Stephanie
    Voi, Maurizio
    de Vries, Elisabeth G. E.
    Baudin, Eric
    Yao, James C.
    PANCREAS, 2017, 46 (06) : 751 - 757
  • [33] Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus
    Cella, C. A.
    Barberis, M.
    Spada, F.
    Pisa, E.
    Laffi, A.
    Gritti, S.
    Leone, I
    Zanetti, C.
    Fazio, N.
    NEUROENDOCRINOLOGY, 2018, 106 : 4 - 4
  • [34] Angiogenic Circulating Biomarkers in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus
    Cella, C. A.
    Spada, F.
    Labanca, V
    Radice, D.
    Rubino, M.
    Zorzino, L.
    Fazio, N.
    NEUROENDOCRINOLOGY, 2017, 105 : 3 - 3
  • [35] Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours
    Raymond, Eric
    Kulke, Matthew H.
    Qin, Shukui
    Yu, Xianjun
    Schenker, Michael
    Cubillo, Antonio
    Lou, Wenhui
    Tomasek, Jiri
    Thiis-Evensen, Espen
    Xu, Jian-Ming
    Croitoru, Adina E.
    Khasraw, Mustafa
    Sedlackova, Eva
    Borbath, Ivan
    Ruff, Paul
    Oberstein, Paul E.
    Ito, Tetsuhide
    Jia, Liqun
    Hammel, Pascal
    Shen, Lin
    Shrikhande, Shailesh V.
    Shen, Yali
    Sufliarsky, Jozef
    Khan, Gazala N.
    Morizane, Chigusa
    Galdy, Salvatore
    Khosravan, Reza
    Fernandez, Kathrine C.
    Rosbrook, Brad
    Fazio, Nicola
    NEUROENDOCRINOLOGY, 2018, 107 (03) : 237 - 245
  • [36] Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after 177Lu-octreotate
    Kamp, Kimberly
    Gumz, Brenda
    Feelders, Richard A.
    Kwekkeboom, Dik J.
    Kaltsas, Gregory
    Costa, Frederico P.
    de Herder, Wouter W.
    ENDOCRINE-RELATED CANCER, 2013, 20 (06) : 825 - 831
  • [37] Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)
    Vernieri, Claudio
    Pusceddu, Sara
    Fuca, Giovanni
    Indelicato, Pietro
    Centonze, Giovanni
    Castagnoli, Lorenzo
    Ferrari, Elisa
    Ajazi, Arta
    Pupa, Serenella
    Casola, Stefano
    Foiani, Marco
    Mazzaferro, Vincenzo
    Pruneri, Giancarlo
    Milione, Massimo
    de Braud, Filippo
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (07) : 1704 - 1712
  • [38] Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors
    Bisht, Savita
    Feldmann, Georg
    Brossart, Peter
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (06) : 777 - 788
  • [39] Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
    Yao, James C.
    Lombard-Bohas, Catherine
    Baudin, Eric
    Kvols, Larry K.
    Rougier, Philippe
    Ruszniewski, Philippe
    Hoosen, Sakina
    St Peter, Jessica
    Haas, Tomas
    Lebwohl, David
    Van Cutsem, Eric
    Kulke, Matthew H.
    Hobday, Timothy J.
    O'Dorisio, Thomas M.
    Shah, Manisha H.
    Cadiot, Guillaume
    Luppi, Gabriele
    Posey, James A.
    Wiedenmann, Bertram
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 69 - 76
  • [40] Role of Radiomics in the Everolimus response prediction of metastatic neuroendocrine tumors
    Magi, L.
    Polici, M.
    Zerunian, M.
    Rinzivillo, M.
    Marasco, M.
    Iannicelli, E.
    Caruso, D.
    Annibale, B.
    Laghi, A.
    Panzuto, F.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 129 - 129
12345